The approach uses an iteration of the SHERLOCK technology exclusively licensed to OraSure Technologies' subsidiary, Sherlock Biosciences.

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) system ...

Various approaches have been developed to identify and quantitate copy-number variation. A new, high-resolution approach that already shows promise is digital PCR. As illustrated by many research ...

Use of an advanced form of the commonly used polymerase chain reaction (PCR) method to analyze circulating tumor cells (CTCs) may greatly increase the ability to diagnose early-stage cancer, ...

Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for ...

Philadelphia, March 27, 2025 – Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), ...

Digital PCR (dPCR) has emerged as a powerful tool in genetic analysis, offering improved precision, sensitivity, and accuracy compared to traditional methods. In this webinar, we will provide an ...

Venlo, the Netherlands, Sept. 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced an important milestone with the launch of 100 new assays for its digital ...

FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 ...

BOSTON--(BUSINESS WIRE)--Stilla Technologies and Atila BioSystems today announced an agreement to market digital PCR kits and assays produced by Atila BioSystems for use on the naica® system (Stilla ...

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and GENCURIX, Inc. (KOSDAQ: 229000) today announced a new partnership to develop oncology assays for use on the QIAcuityDx platform, a ...

HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of four new ...